Clinical Trial: A Phase Ia, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SQ-23101 Injection in Patients with Thyroid Eye Disease (China)

China, Sept. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Phase Ia, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SQ-23101 Injection in Patients with Thyroid Eye Disease'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133597

Registration Time: 2026/09/29

Type: Interventional study

Primary Sponsor: Shanghai Ninth Peoples Hospital,Shanghai JiaoTong University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=345758

Published by HT Digital Content Services with...